299 related articles for article (PubMed ID: 20542984)
1. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
4. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
5. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients.
Kramer M; Amer R; Mukamel M; Snir M; Jaouni T; Friling R
Eye (Lond); 2009 Nov; 23(11):2034-41. PubMed ID: 19151650
[TBL] [Abstract][Full Text] [Related]
6. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of infliximab on the acute attack of uveitis.
Alokaily F; Alsaleh S; Al-Balawi M; Al-Rashidi S
Saudi Med J; 2010 Jan; 31(1):82-5. PubMed ID: 20062906
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
10. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
11. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
12. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
[TBL] [Abstract][Full Text] [Related]
13. Infliximab in refractory uveitis due to Behçet's disease.
Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease.
Sugita S; Yamada Y; Mochizuki M
Br J Ophthalmol; 2011 Apr; 95(4):549-52. PubMed ID: 20584716
[TBL] [Abstract][Full Text] [Related]
15. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
17. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
18. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease.
Rosenbaum JT
J Rheumatol; 2004 Jul; 31(7):1241-3. PubMed ID: 15229938
[No Abstract] [Full Text] [Related]
19. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis.
Lee RW; Dick AD
Br J Ophthalmol; 2010 Mar; 94(3):269-70. PubMed ID: 20215370
[No Abstract] [Full Text] [Related]
20. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
[No Abstract] [Full Text] [Related]
[Next] [New Search]